Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Caris Life Sciences (CAI) Operating Expenses (2024 - 2025)

Caris Life Sciences has reported Operating Expenses over the past 2 years, most recently at $204.5 million for Q4 2025.

  • Quarterly results put Operating Expenses at $204.5 million for Q4 2025, up 22.47% from a year ago — trailing twelve months through Dec 2025 was $755.0 million (changed N/A YoY), and the annual figure for FY2025 was $766.9 million, up 14.57%.
  • Operating Expenses for Q4 2025 was $204.5 million at Caris Life Sciences, up from $184.2 million in the prior quarter.
  • Over the last five years, Operating Expenses for CAI hit a ceiling of $204.5 million in Q4 2025 and a floor of $162.5 million in Q3 2024.